Mizuho Securities Sticks to Their Buy Rating for IN8bio (INAB)
Mizuho Securities analyst Uy Ear maintained a Buy rating on IN8bio (INAB – Research Report) today and set a price target of $2.00. The ...
Insmed (INSM) Gets a Buy from Mizuho Securities
Mizuho Securities analyst Graig Suvannavejh maintained a Buy rating on Insmed (INSM – Research Report) today and set a price target of $96.00.
CNN1y
Mizuho Financial Group Inc Sponsored ADR
Mizuho Financial Group, Inc. operates as a holding company which engages in the provision of financial services such as banking, trust banking, securities, and others. It operates through the ...
朝日新聞社1mon
Mizuho warned by regulator for setting IPO prices too low
The Japan Fair Trade Commission on April 13 rebuked Mizuho Securities Co. for setting initial public offering (IPO) prices of newly listed stocks too low, which could lead to violating the Anti ...